Published May 11, 2022 | Version v1
Journal article Open

An Insight into the Epidemiology and Genetic Diversity of Hepatitis B Virus in Africa

  • 1. Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.

Description

Abstract

Hepatitis viruses (hepatotropic viruses) are classified into five kinds, denoted by the letters A, B, C, D, and E, each with its own unique genotypes, clinical implications, and geographic distribution. Viral hepatitis is a type of liver inflammation that can resolve on its own or proceed to cirrhosis or hepatocellular cancer. Hepatitis A, B, and C infections are the most common types of infectious viral hepatitis. Over the previous five decades, hepatitis B virus (HBV) infection has exhibited an intermediate or high endemicity level in low-income nations. HBV genotype variation is thought to be crucial in regulating disease development, infection outcome, antiviral therapy response, and illness prognosis. HBV is divided into ten genotypes (A-J) and roughly 40 sub-genotypes, correlated with different geographic distributions, transmission routes, and disease progression. The goal of this study was to figure out the current status of HBV prevalence and genotype distribution in West African countries. HBV genotypes A, D, and E have been reported the most widely prevalent genotypes in Africa so far, while there are limited reports of genotypes B and C. HBV genotype A is shown to be more prevalent in Africa than on other continents, implying that it has an African origin. Genotype D has been found across Africa, particularly in the Mediterranean and North African regions. Except in Africa, HBV genotype E infection is extremely rare, even when infection with this genotype has been recorded outside of Africa, it has virtually always been in African origin people. Within Africa, HBV genotype E is abundant and broad across the continent, reaching from Senegal's west coast to Namibia's southwestern tip and eastward to the Central African Republic. These epidemiological findings and differences have important implications for the immunization, antiviral therapy, and clinical outcomes of HBV on a national and regional level.

Özet

Hepatit virüsleri (hepatotropik virüsler) A, B, C, D ve E harfleriyle ifade edilen beş türe ayrılır ve her birinin kendine özgü genotipleri, klinik sonuçları ve coğrafi dağılımları bulunur. Viral hepatit, tedavi edilmeksizin düzelebilen ya da siroz veya hepatosellüler kansere ilerleyebilen bir tür karaciğer inflamasyonudur. Hepatit A, B ve C enfeksiyonları enfeksiyöz viral hepatitin en yaygın tipleridir. Hepatit B virusu (HBV) enfeksiyonu son elli yıllık dönemde düşük gelirli ülkelerde orta veya yüksek endemisite düzeyi sergilemiştir. HBV genotip varyasyonunun hastalık gelişiminin düzenlenmesini, enfeksiyon sonucunu, antiviral tedavi yanıtını ve hastalık prognozunu belirlemede çok önemli olduğu düşünülmektedir. HBV coğrafi dağılımları, bulaşma yolları ve hastalık progresyonundaki farklılıkları ile ilişkili olarak on genotipe (A-J) ve kabaca 40 alt genotipe ayrılmıştır. Bu çalışmanın amacı, Batı Afrika ülkelerindeki HBV prevalansı ve genotip dağılımının güncel durumunu ortaya koymaktır. Şimdiye kadar HBV A, D ve E genotipleri Afrika'da en yaygın raporlanan genotipler olurken, genotip B ve C'yi içeren sınırlı sayıda rapor bulunmaktadır. HBV genotip A'nın Afrika'da diğer kıtalara göre daha yaygın olduğu gösterilmiştir ve bu da bu genotipin Afrika kökenli olduğunu düşündürmektedir. Genotip D, Afrika genelinde, özellikle Akdeniz ve Kuzey Afrika bölgelerinde bulunmuştur. HBV genotip E enfeksiyonu ise Afrika dışında son derece nadirdir, öyle ki bu genotip ile enfeksiyon Afrika dışında kaydedilmiş olsa bile neredeyse her zaman Afrika kökenli insanlarda saptanmıştır. HBV genotip E Afrika'da kıta genelinde yaygındır ve Senegal'in batı kıyısından Namibya'nın güneybatı ucuna ve doğuda Orta Afrika Cumhuriyeti'ne kadar geniş bir alana yayılmıştır. Bu epidemiyolojik bulguların ve farklılıkların HBV bağışıklaması, antiviral tedavi ve ulusal ve bölgesel düzeyde klinik sonuçlar üzerinde önemli etkileri vardır.

Notes

Hepatit B Virusunun Afrika'daki Epidemiyolojisine ve Genetik Çeşitliliğine Bakış

Files

jmvi.2022.50.z.pdf

Files (1.1 MB)

Name Size Download all
md5:d993b87e556c1aa942c67e2e76eddaea
1.1 MB Preview Download

Additional details

References

  • ‎1. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61(10): ‎‎1942-56. ‎
  • ‎2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of ‎chronic hepatitis ‎B virus infection: a systematic review of data published between 1965 and 2013. ‎Lancet 2015; 386(10003): ‎‎1546-55.
  • ‎3. World Health Organization (WHO), Geneva, Switzerland. Hepatitis B. Available at: ‎https://www.who.int/news-‎room/fact-sheets/detail/hepatitis-b [Accessed July 27, 2021].‎
  • ‎4. Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al; Gastroenterology and Hepatology ‎‎Association of sub-Saharan Africa (GHASSA). Hepatitis B in sub-Saharan Africa: strategies to achieve the ‎‎2030 ‎elimination targets. Lancet Gastroenterol Hepatol 2017; 2(12): 900-9. ‎
  • ‎5. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new ‎estimates of ‎age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30(12): 2212-9. ‎
  • ‎6. International Committee on Taxonomy of Viruses, Washington, DC. Virus Taxonomy: 2020, October. ‎Available ‎at: https://talk.ictvonline.org/taxonomy/ [Accessed September 16, 2021]. ‎
  • ‎7. Chen C, Jia H, Zhang F, Qin Y, Zong L, Yuan Q, et al. Functional characterization of hepatitis B virus ‎core ‎promoter mutants revealed transcriptional interference among co-terminal viral mRNAs. J Gen ‎Virol 2016; ‎‎97(10): 2668-76. ‎
  • ‎8. Hayashi S, Nagaoka K, Tanaka Y. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular ‎‎Carcinoma, Including the Viral Genome and Glycosylated Proteins. Int J Mol Sci 2021; 22(20): 11051. ‎
  • ‎9. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. ‎Hepatoma Res ‎‎2016; 2: 163-86. ‎
  • ‎10. Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Hosseini Razavi A, Sharifian A. Characterization of ‎the "a" ‎determinant region of the hepatitis B virus genome in Iranian patients at different clinical ‎phases of chronic ‎infection. Gastroenterol Hepatol Bed Bench 2018; 11(2): 131-7. ‎
  • ‎11. Şahiner F. Hepatitis B virus virion structure and genome organization. In: tibbiviroloji.com, Türkiye. ‎Available ‎at: http://tibbiviroloji.com/4/tr/virology/en.1.HBV.virion.genom.png [Accessed April 13, ‎‎2022]. ‎
  • ‎12. Thomas HC, Lemon S, Zuckerman AJ. Viral Hepatitis. In: Kann M, Gerlich WH (eds), Structure and ‎molecular ‎virology (3rd edition). 2005, Blackwell Publishing, Oxford. pp:149-180. ‎
  • ‎13. Howard CR, Allison LM. Hepatitis B surface antigen variation and protective immunity. Intervirology ‎‎1995; ‎‎38(1-2): 35-40. ‎
  • ‎14. Waters JA, O'Rourke SM, Richardson SC, Papaevangelou G, Thomas HC. Qualitative analysis of the ‎humoral ‎immune response to the "a" determinant of HBs antigen after inoculation with plasma-‎derived or recombinant ‎vaccine. J Med Virol 1987; 21(2): 155-60. ‎
  • ‎15. Gish RG, Basit SA, Ryan J, Dawood A, Protzer U. Hepatitis B Core Antibody: Role in Clinical Practice ‎in 2020. ‎Curr Hepatology Rep 2020; 19: 254-65. ‎
  • ‎16. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer ‎Lett 2007; ‎‎252(2): 157-70. ‎
  • ‎17. Diao J, Garces R, Richardson CD. X protein of hepatitis B virus modulates cytokine and growth factor ‎related ‎signal transduction pathways during the course of viral infections and hepatocarcinogenesis. ‎Cytokine Growth ‎Factor Rev 2001; 12(2-3): 189-205. ‎
  • ‎18. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular ‎carcinoma. ‎J Gastroenterol Hepatol 2011; Suppl 1: 144-52. ‎
  • ‎19. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016; 64(1 ‎Suppl): ‎S4-S16. ‎
  • ‎20. Şahiner F. Cellular replication cycle of hepatitis B virus. In: tibbiviroloji.com, Türkiye. Available at: ‎‎http://tibbiviroloji.com/4/tr/virology/en.2.HBV.replication.png [Accessed April 13, 2022]. ‎
  • ‎21. Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral ‎Res 2020; ‎‎180: 104824. ‎
  • ‎22. ViralZone, Swiss Institute of Bioinformatics, Switzerland. Hepadnaviridae. Available at: ‎‎https://viralzone.expasy.org/30?outline=all_by_species [Accessed December 18, 2021]. ‎
  • ‎23. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; ‎‎52(2): ‎‎282-4. ‎
  • ‎24. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med 2015; ‎‎5(5): ‎a021410. ‎
  • ‎25. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol 2011; ‎‎17(2): ‎‎87-95. ‎
  • ‎26. Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, ‎treatment ‎and care: a review. Occup Med (Lond) 2011; 61(8): 531-40. ‎
  • ‎27. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J ‎Surg Oncol ‎‎2005; 3: 27. ‎
  • ‎28. World Health Organization (WHO), Geneva, Switzerland. Global Health Sector Strategy on Viral ‎Hepatitis ‎‎2016–2021, Towards Ending Viral Hepatitis. Available at: ‎‎https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf [Accessed ‎December 27, ‎‎2021]. ‎
  • ‎29. Büchner A, Du Plessis NM, Reynders DT, Omar FE, Mayaphi SH, Haeri Mazanderani AF, et al. ‎Nosocomial ‎outbreak of hepatitis B virus infection in a pediatric hematology and oncology unit in South ‎Africa: ‎Epidemiological investigation and measures to prevent further transmission. Pediatr Blood ‎Cancer 2015; 62(11): ‎‎1914-9. ‎
  • ‎30. Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: ‎strategies for a ‎global approach. J Hepatol 2015; 62(2): 469-76. ‎
  • ‎31. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of ‎‎Vaccination on Disease. Clin Liver Dis 2016; 20(4): 607-28. ‎
  • ‎32. Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell ‎‎2016; ‎‎3(9): 420-37 ‎
  • ‎33. Tran TT. Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med 2009; 76 ‎Suppl 3: ‎S25-9. ‎
  • ‎34. Borgia G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol 2012; ‎‎18(34): ‎‎4677-83. ‎
  • ‎35. Biset Ayalew M, Adugna Horsa B. Hepatitis B Vaccination Status among Health Care Workers in a ‎Tertiary ‎Hospital in Ethiopia. Hepat Res Treat 2017; 2017: 6470658. ‎
  • ‎36. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; ‎‎14(1): ‎‎1-21, vii. ‎
  • ‎37. Hwang EW, Cheung R. Global epidemiology of hepatitis B virus (HBV) infection. N Am J Med Sci ‎‎2011; 4(1): ‎‎7-13. ‎
  • ‎38. Ige TA, Hasford S, Tabakov S, Trauernicht CJ, Rule A, Azangwe G, et al. Medical Physics ‎Development in ‎Africa - Status, Education, Challenges, Future. Medical Physics International 2020; 8(1) ‎Special Issue, History of ‎Medical Physics 3: 303-16.‎
  • ‎39. World Health Organization (WHO), Geneva, Switzerland. Global progress report on HIV, viral ‎hepatitis and ‎sexually transmitted infections, 2021. Available at: ‎https://www.who.int/publications/i/item/9789240027077 ‎‎[Accessed December 27, 2021]. ‎
  • ‎40. Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, et al. Genetic diversity of ‎hepatitis ‎viruses in West-African countries from 1996 to 2018. World J Hepatol 2018; 10(11): 807-21. ‎
  • ‎41. Abesig J, Chen Y, Wang H, Sompo FM, Wu IXY. Prevalence of viral hepatitis B in Ghana between ‎‎2015 and ‎‎2019: A systematic review and meta-analysis. PLoS One 2020; 15(6): e0234348. ‎
  • ‎42. Ajuwon BI, Yujuico I, Roper K, Richardson A, Sheel M, Lidbury BA. Hepatitis B virus infection in ‎Nigeria: a ‎systematic review and meta-analysis of data published between 2010 and 2019. BMC Infect ‎Dis 2021; 21(1): ‎‎1120. ‎
  • ‎43. Jaquet A, Wandeler G, Tine J, Diallo MB, Manga NM, Dia NM, et al. Prevention and Care of Hepatitis ‎B in ‎Senegal; Awareness and Attitudes of Medical Practitioners. Am J Trop Med Hyg 2017; 97(2): 389-‎‎95. ‎
  • ‎44. Sebastião CS, Neto Z, Jandondo D, Mirandela M, Morais J, Brito M. HIV, hepatitis B virus, hepatitis C ‎virus, ‎and syphilis among pregnant women attending antenatal care in Luanda, Angola: Seroprevalence ‎and risk factors. ‎J Med Virol 2020 [Epub ahead of print]. ‎
  • ‎45. Kodjoh N. Fighting viral hepatitis B and C in Africa. Focus on Benin. Med Sante Trop 2015; 25(2): ‎‎141-4. ‎‎ ‎
  • ‎46. Meda N, Tuaillon E, Kania D, Tiendrebeogo A, Pisoni A, Zida S, et al. Hepatitis B and C virus ‎seroprevalence, ‎Burkina Faso: a cross-sectional study. Bull World Health Organ 2018; 96(11): 750-9. ‎
  • ‎47. Noubiap JJ, Joko WY, Nansseu JR, Tene UG, Siaka C. Sero-epidemiology of human ‎immunodeficiency virus, ‎hepatitis B and C viruses, and syphilis infections among first-time blood ‎donors in Edéa, Cameroon. Int J Infect ‎Dis 2013; 17(10): e832-7. ‎
  • ‎48. Apata IW, Averhoff F, Pitman J, Bjork A, Yu J, Amin NA, et al; Centers for Disease Control and ‎Prevention ‎‎(CDC). Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C ‎infection--sub-Saharan ‎Africa, 2000-2011. MMWR Morb Mortal Wkly Rep 2014; 63(29): 613-9. ‎
  • ‎49. Atipo-Ibara BI, Itoua-Ngaporo AN, Dzia-Lepfoundzou A, Ahoui-Apendi C, Deby-Gassaye C, Bossali F, ‎et al. ‎Hepatitis B virus in Congo (Brazzaville): prevalence and genetic diversity among blood donors in ‎hyper endemic ‎areas. J Afr Hepato Gastroenterol 2015; 9: 127-31. ‎
  • ‎50. Seri B, Minga A, Gabillard D, Dembele B, Konate S, Le Carrou J, et al. Twenty-Year Evolution of ‎Hepatitis B ‎Virus and Human Immunodeficiency Virus Prevalence and Incidence in Voluntary Blood ‎Donors in Côte d'Ivoire. ‎Open Forum Infect Dis 2018; 5(4): ofy060. ‎
  • ‎51. Ismail SA, Cuadros DF, Benova L. Hepatitis B in Egypt: A cross-sectional analysis of prevalence and risk ‎‎factors for active infection from a nationwide survey. Liver Int 2017; 37(12): 1814-22. ‎
  • ‎52. Yazie TD, Tebeje MG. An updated systematic review and meta-analysis of the prevalence of hepatitis B ‎virus ‎in Ethiopia. BMC Infect Dis 2019; 19(1): 917. ‎
  • ‎53. Eko Mba JM, Bisseye C, Ntsame Ndong JM, Mombo LE, Bengone C, Mouelet Migolet G, et al. Prevalent ‎‎hepatitis B surface antigen among first-time blood donors in Gabon. PLoS One 2018; 13(4): e0194285. ‎
  • ‎54. Bittaye M, Idoko P, Ekele BA, Obed SA, Nyan O. Hepatitis B virus sero-prevalence amongst pregnant ‎women ‎in the Gambia. BMC Infect Dis 2019; 19(1): 259. ‎
  • ‎55. Daw MA, El-Bouzedi A; In association with Libyan Study Group of Hepatitis & HIV. Prevalence of hepatitis ‎B ‎and hepatitis C infection in Libya: results from a national population based survey. BMC Infect Dis 2014; 14: ‎‎17.‎
  • ‎56. Stockdale AJ, Mitambo C, Everett D, Geretti AM, Gordon MA. Epidemiology of hepatitis B, C and D in ‎Malawi: ‎systematic review. BMC Infect Dis 2018; 18(1): 516. ‎
  • ‎57. Jary A, Dienta S, Leducq V, Le Hingrat Q, Cisse M, Diarra AB, et al. Seroprevalence and risk factors for HIV, ‎‎HCV, HBV and syphilis among blood donors in Mali. BMC Infect Dis 2019; 19(1): 1064. ‎
  • ‎58. Mansour W, Malick FZ, Sidiya A, Ishagh E, Chekaraou MA, Veillon P, et al. Prevalence, risk factors, and ‎‎molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in ‎Mauritania. J ‎Med Virol 2012; 84(8): 1186-98. ‎
  • ‎59. Cunha L, Plouzeau C, Ingrand P, Gudo JP, Ingrand I, Mondlane J, et al. Use of replacement blood donors ‎to ‎study the epidemiology of major blood-borne viruses in the general population of Maputo, Mozambique. ‎J Med ‎Virol 2007; 79(12): 1832-40. ‎
  • ‎60. Viegas EO, Tembe N, Macovela E, Gonçalves E, Augusto O, Ismael N, et al. Incidence of HIV and the ‎‎prevalence of HIV, hepatitis B and syphilis among youths in Maputo, Mozambique: a cohort study. PLoS One ‎‎‎2015; 10(3): e0121452. ‎
  • ‎61. Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, et al. Prevalence of ‎‎hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infect Dis 2019; ‎‎19(1): ‎‎381. ‎
  • ‎‎62. Yambasu EE, Reid A, Owiti P, Manzi M, Murray MJS, Edwin AK. Hidden dangers-prevalence of blood ‎borne ‎pathogens, hepatitis B, C, HIV and syphilis, among blood donors in Sierra Leone in 2016: opportunities ‎for ‎improvement: a retrospective, cross-sectional study. Pan Afr Med J 2018; 30: 44. ‎
  • ‎63. Samsunder N, Ngcapu S, Lewis L, Baxter C, Cawood C, Khanyile D, et al. Seroprevalence of hepatitis B ‎virus: ‎Findings from a population-based household survey in KwaZulu-Natal, South Africa. Int J Infect Dis ‎‎2019; 85: ‎‎150-7. ‎
  • ‎64. Badawi MM, Atif MS, Mustafa YY. Systematic review and meta-analysis of HIV, HBV and HCV infection ‎‎prevalence in Sudan. Virol J 2018; 15(1): 148. ‎
  • ‎65. Kirbak ALS, Ng'ang'a Z, Omolo J, Idris H, Usman A, Mbabazi WB. Sero-prevalence for Hepatitis B virus ‎among ‎pregnant women attending antenatal clinic in Juba Teaching Hospital, Republic of South Sudan. Pan ‎Afr Med J ‎‎2017; 26: 72. ‎
  • ‎66. Mueller A, Stoetter L, Kalluvya S, Stich A, Majinge C, Weissbrich B, et al. Prevalence of hepatitis B virus ‎‎infection among health care workers in a tertiary hospital in Tanzania. BMC Infect Dis 2015; 15: 386. ‎
  • ‎67. Kitandwe PK, Muyanja E, Nakaweesa T, Nanvubya A, Ssetaala A, Mpendo J, et al. Hepatitis B prevalence ‎and ‎incidence in the fishing communities of Lake Victoria, Uganda: a retrospective cohort study. BMC Public ‎Health ‎‎2021; 21(1): 394. ‎
  • ‎68. Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Zanolini A, Saag M, et al. Eligibility for hepatitis B ‎antiviral ‎therapy among adults in the general population in Zambia. PLoS One 2020; 15(1): e0227041. ‎
  • ‎69. Dzingirai B, Katsidzira L, Matyanga CMJ, Postma MJ, van Hulst M, Mafirakureva N. Progress on the ‎elimination ‎of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges. J Viral Hepat ‎‎2021; 28(7): ‎‎994-1002. ‎
  • ‎70. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J 2013; 10: 239. ‎ ‎
  • ‎71. Liu Z, Zhang Y, Xu M, Li X, Zhang Z. Distribution of hepatitis B virus genotypes and subgenotypes: A meta-‎‎analysis. Medicine (Baltimore) 2021; 100(50): e27941. ‎
  • ‎72. Fujiwara K. Novel Genetic Rearrangements in Hepatitis B Virus: Complex Structural Variations and ‎Structural ‎Variation Polymorphisms. Viruses 2021; 13(3): 473. ‎
  • ‎73. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J ‎‎Virol 2008; 82(11): 5657-63. ‎
  • ‎74. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B ‎‎virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally ‎‎assigned to new genotype J. J Virol 2009; 83(20): 10538-47. ‎
  • ‎75. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol ‎‎‎2014; 20(18): 5427-34. ‎
  • ‎76. Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med 2015; 5(5): ‎‎a021436. ‎
  • ‎77. Seo Y, Yano Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. ‎World J ‎Gastroenterol 2014; 20(37): 13284-92. ‎
  • ‎78. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. ‎‎Hepatol Res 2010; 40(1): 14-30. ‎
  • ‎79. Andernach IE, Hübschen JM, Muller CP. Hepatitis B virus: the genotype E puzzle. Rev Med Virol 2009; ‎‎19(4): ‎‎231-40. ‎
  • ‎80. Lago BV, Mello FC, Kramvis A, Niel C, Gomes SA. Hepatitis B virus subgenotype A1: evolutionary ‎relationships ‎between Brazilian, African and Asian isolates. PLoS One 2014; 9(8): e105317. ‎
  • ‎81. Shi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, et al. Hepatitis B virus subgenotyping: history, effects of ‎‎recombination, misclassifications, and corrections. Infect Genet Evol 2013; 16: 355-61. [81]‎
  • ‎82. Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of ‎hepatitis B ‎virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J ‎Gastroenterol ‎‎2014; 20(23): 7152-68. ‎
  • ‎83. de Pina-Araujo IIM, Spitz N, Soares CC, Niel C, Lago BV, Gomes SA. Hepatitis B virus genotypes A1, A2 and ‎E ‎in Cape Verde: Unequal distribution through the islands and association with human flows. PLoS One 2018; ‎‎‎13(2): e0192595. ‎
  • ‎84. Kurbanov F, Tanaka Y, Fujiwara K, Sugauchi F, Mbanya D, Zekeng L, et al. A new subtype (subgenotype) ‎Ac ‎‎(A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 2005; ‎‎86(Pt 7): ‎‎2047-56. ‎
  • ‎85. Olinger CM, Venard V, Njayou M, Oyefolu AOB, Maïga I, Kemp AJ, et al. Phylogenetic analysis of the ‎‎precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and ‎‎recombinations. J Gen Virol 2006; 87(Pt 5): 1163-73. ‎
  • ‎86. Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Maes P, Van Ranst M. Novel hepatitis B virus subgenotype ‎A6 ‎in African-Belgian patients. J Clin Virol 2010; 47(1): 93-6. ‎
  • ‎87. Hübschen JM, Mbah PO, Forbi JC, Otegbayo JA, Olinger CM, Charpentier E, et al. Detection of a new ‎‎subgenotype of hepatitis B virus genotype A in Cameroon but not in neighbouring Nigeria. Clin Microbiol ‎Infect ‎‎2011; 17(1): 88-94. ‎
  • ‎88. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J ‎Hepatol ‎‎2011; 55(1): 183-91. ‎
  • ‎89. Matthews PC, Beloukas A, Malik A, Carlson JM, Jooste P, Ogwu A, et al. Prevalence and Characteristics of ‎‎Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. PLoS One ‎‎2015; ‎‎10(7): e0134037. ‎
  • ‎90. Gopalakrishnan D, Keyter M, Shenoy KT, Leena KB, Thayumanavan L, Thomas V, et al. Hepatitis B virus ‎‎subgenotype A1 predominates in liver disease patients from Kerala, India. World J Gastroenterol 2013; ‎‎19(48): ‎‎9294-306. ‎
  • ‎91. Kramvis A, Kew MC. Molecular characterization of subgenotype A1 (subgroup Aa) of hepatitis B virus. ‎Hepatol ‎Res 2007; 37(s1): S27-32. ‎
  • ‎92. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of ‎chronic ‎hepatitis B. Hepatol Int 2009; 3(2): 334-42. ‎
  • ‎93. Forbi JC, Ben-Ayed Y, Xia GL, Vaughan G, Drobeniuc J, Switzer WM, et al. Disparate distribution of ‎hepatitis B ‎virus genotypes in four sub-Saharan African countries. J Clin Virol 2013; 58(1): 59-66. ‎
  • ‎94. Khatun M, Mondal RK, Pal S, Baidya A, Bishnu D, Banerjee P, et al. Distinctiveness in virological features ‎and ‎pathogenic potentials of subgenotypes D1, D2, D3 and D5 of Hepatitis B virus. Sci Rep 2018; 8(1): 8055. ‎ ‎
  • ‎95. Matlou MK, Gaelejwe LR, Musyoki AM, Rakgole JN, Selabe SG, Amponsah-Dacosta E. A novel hepatitis B ‎virus ‎recombinant genotype D4/E identified in a South African population. Heliyon 2019; 5(4): e01477. ‎
  • ‎96. Hundie GB, Stalin Raj V, Gebre Michael D, Pas SD, Koopmans MP, Osterhaus AD, et al. A novel hepatitis B ‎‎virus subgenotype D10 circulating in Ethiopia. J Viral Hepat 2017; 24(2): 163-73. ‎
  • ‎97. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in ‎‎developing countries. World J Gastroenterol 2015; 21(42): 11941-53. ‎
  • ‎98. Meldal BHM, Moula NM, Barnes IHA, Boukef K, Allain JP. A novel hepatitis B virus subgenotype, D7, in ‎‎Tunisian blood donors. J Gen Virol 2009; 90(Pt 7): 1622-8. ‎
  • ‎99. Abdou Chekaraou M, Brichler S, Mansour W, Le Gal F, Garba A, Dény P, et al. A novel hepatitis B virus ‎‎(HBV) ‎subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in ‎Niger along ‎with HBV/E strains. J Gen Virol 2010; 91(Pt 6): 1609-20. ‎
  • ‎100. Kostaki EG, Karamitros T, Stefanou G, Mamais I, Angelis K, Hatzakis A, et al. Unravelling the history of ‎‎hepatitis B virus genotypes A and D infection using a full-genome phylogenetic and phylogeographic ‎approach. ‎Elife 2018; 7: e36709. ‎
  • ‎‎‎101. Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Jpn J Infect Dis 2012; ‎‎65(6): ‎‎476-82. ‎
  • ‎102. Odemuyiwa SO, Mulders MN, Oyedele OI, Ola SO, Odaibo GN, Olaleye DO, et al. Phylogenetic analysis ‎of new ‎hepatitis B virus isolates from Nigeria supports endemicity of genotype E in West Africa. J Med Virol ‎‎2001; 65(3): ‎‎463-9. ‎
  • ‎103. Suzuki S, Sugauchi F, Orito E, Kato H, Usuda S, Siransy L, et al. Distribution of hepatitis B virus (HBV) ‎‎genotypes among HBV carriers in the Cote d'Ivoire: complete genome sequence and phylogenetic ‎relatedness of ‎HBV genotype E. J Med Virol 2003; 69(4): 459-65. ‎
  • ‎104. Bekondi C, Olinger CM, Boua N, Talarmin A, Muller CP, Le Faou A, et al. Central African Republic is part ‎of ‎the West-African hepatitis B virus genotype E crescent. J Clin Virol 2007; 40(1): 31-7. ‎
  • ‎105. Cuenca-Gómez JÁ, Lozano-Serrano AB, Cabezas-Fernández MT, Soriano-Pérez MJ, Vázquez-Villegas J, ‎‎Estévez-Escobar M, et al. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide ‎treatment ‎in real clinical practice. BMC Infect Dis 2018; 18(1): 568. ‎
  • ‎106. Hübschen JM, Andernach IE, Muller CP. Hepatitis B virus genotype E variability in Africa. J Clin Virol ‎‎2008; ‎‎43(4): 376-80. ‎
  • ‎107. Norder H, Hammas B, Löfdahl S, Couroucé AM, Magnius LO. Comparison of the amino acid sequences ‎of nine ‎different serotypes of hepatitis B surface antigen and genomic classification of the corresponding ‎hepatitis B virus ‎strains. J Gen Virol 1992; 73(Pt 5): 1201-8. ‎
  • ‎108. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; ‎‎‎87(3A): 14S-20S. ‎
  • ‎109. Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Hum Vaccin ‎Immunother ‎‎2020; 16(7): 1533-44. ‎
  • ‎110. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal ‎‎insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8(2): 235-‎‎47. ‎
  • ‎111. World Health Organization (WHO), Geneva, Switzerland. WHO: Vaccines and Biologicals: WHO Vaccine-‎‎preventable Diseases: Monitoring System: 2002 Global Summary: Department of Vaccines and Other ‎Biologicals, ‎World Health Organization; 2002. ‎‎[https://apps.who.int/immunization_monitoring/globalsummary/]‎
  • ‎112. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J ‎‎Hepatol 2015; 7(18): 2127-32. ‎